SCHEMBL10143645

SCHEMBL10143645

Cc1ccn2cc(C)nc2n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 4/20 0.38
PDE8B O95263 1/20 0.36
GRM5 P41594 6/20 0.35
HDAC1 Q13547 1/20 0.35
RAB9A P51151 3/20 0.33
NPC1 O15118 2/20 0.33
CCR1 P32246 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
ADORA3 P0DMS8 1/20 0.33
ADORA2A P29274 1/20 0.33
CCR5 P51681 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
KMT2A Q03164 1/20 0.33
MAPT P10636 1/20 0.33
ATM Q13315 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
PARP1 P09874 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12402544 0.83 PDE10A (0.35) PDE10APDE8BHDAC1RAB9ANPC1
SCHEMBL25044484 0.83 PDE8B (0.39) PDE10APDE8BRAB9ANPC1ADORA3
SCHEMBL20162086 0.83 HDAC1 (0.35) PDE10AGRM5HDAC1RAB9ANPC1
SCHEMBL25124896 0.83 PDE10A (0.35) PDE10APDE8BRAB9ANPC1KDM4E
SCHEMBL17626629 0.83 SUV39H2 (0.44) PDE10APDE8BGRM5HDAC1ADORA3
SCHEMBL12341046 0.80 PDE10A (0.33) PDE10AGRM5HDAC1RAB9ANPC1
SCHEMBL12343964 0.80 PDE8B (0.35) PDE10APDE8BGRM5HDAC1RAB9A
SCHEMBL25246739 0.78 PDE8B (0.42) PDE10APDE8BRAB9ANPC1SMN1; SMN2
SCHEMBL20344162 0.78 PDE10A (0.33) PDE10AHDAC1
SCHEMBL17285646 0.78 HDAC1 (0.35) PDE10AHDAC1CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230330249-A1 ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF GENENTECH, INC. (US) 2023-10-19 US disclosed
WO-2023018648-A1 PHENOL DERIVATIVES FOR USE IN THE MODULATION OF BRM GENENTECH, INC. (US) 2023-02-16 WO disclosed
EP-3145930-B1 FUSED TRIAZOLE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS Celon Pharma Sa (PL) 2018-07-04 EP disclosed
US-9985213-B2 Compound, material for organic electroluminescence element, organic electroluminescence element, and electronic apparatus IDEMITSU KOSAN CO., LTD. (JP) 2018-05-29 US disclosed
US-9985213-B2 Compound, material for organic electroluminescence element, organic electroluminescence element, and electronic apparatus IDEMITSU KOSAN CO., LTD. (JP) 2018-05-29 US disclosed
US-20170324039-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC APPARATUS IDEMITSU KOSAN CO., LTD. (JP) 2017-11-09 US disclosed
US-20170324039-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC APPARATUS IDEMITSU KOSAN CO., LTD. (JP) 2017-11-09 US disclosed
US-9748494-B2 Compound, material for organic electroluminescence element, organic electroluminescence element, and electronic apparatus IDEMITSU KOSAN CO., LTD. (JP) 2017-08-29 US disclosed
US-9748494-B2 Compound, material for organic electroluminescence element, organic electroluminescence element, and electronic apparatus IDEMITSU KOSAN CO., LTD. (JP) 2017-08-29 US disclosed
US-20170114064-A1 FUSED TRIAZOLE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS CELON PHARMA S.A. (PL) 2017-04-27 US disclosed
US-8865756-B2 Inhibitors of HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2014-10-21 US disclosed
US-20140018399-A1 MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2014-01-16 US disclosed
US-8580828-B2 Mitotic kinesin inhibitors and methods of use thereof ARRAY BIOPHARMA INC. (US) 2013-11-12 US disclosed
US-20130203656-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2013-08-08 US disclosed
US-20130203656-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2013-08-08 US disclosed
US-20130109656-A1 MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF ARRAY BIOPHARMA, INC. 2013-05-02 US disclosed
US-20130096101-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2013-04-18 US disclosed
US-20120115855-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2012-05-10 US disclosed
WO-2011149856-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2011-12-01 WO disclosed
WO-2010065668-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109656-A1 MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF KIF5B, KIF2C, KIFC1 PDE10A 3963/4885PDE8B 2651/4885GRM5 3121/4885
US-20130096101-A1 INHIBITORS OF HCV NS5A HAVCR2, MAVS, EIF2AK2 PDE10A 2981/4885PDE8B 3892/4885GRM5 4687/4885
US-20170114064-A1 FUSED TRIAZOLE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS PDE3B, PDE3A, PDE5A PDE10A 7/4885PDE8B 19/4885GRM5 522/4885
US-20230330249-A1 ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF ADRM1, CD79B, BRDT PDE10A 4726/4885PDE8B 2796/4885GRM5 1067/4885
US-20130203656-A1 INHIBITORS OF HCV NS5A HAVCR2, MAVS, EIF2AK2 PDE10A 2993/4885PDE8B 3910/4885GRM5 4675/4885
US-20140018399-A1 MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF KIF5B, KIF2C, KIFC1 PDE10A 3983/4885PDE8B 2065/4885GRM5 2882/4885
US-20120115855-A1 INHIBITORS OF HCV NS5A HAVCR2, MAVS, EIF2AK2 PDE10A 2993/4885PDE8B 3910/4885GRM5 4675/4885
US-20170324039-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC APPARATUS RER1, OR10J3, LEF1 PDE10A 4371/4885PDE8B 4841/4885GRM5 2523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.